These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 30136337

  • 41. A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation.
    Mezzasalma V, Manfrini E, Ferri E, Sandionigi A, La Ferla B, Schiano I, Michelotti A, Nobile V, Labra M, Di Gennaro P.
    Biomed Res Int; 2016; 2016():4740907. PubMed ID: 27595104
    [Abstract] [Full Text] [Related]

  • 42. No distinction in the gut microbiota between diarrhea predominant-irritable bowel syndrome and healthy subjects: matched case-control study in Thailand.
    Jandee S, Chuensakul S, Maneerat S.
    Gut Pathog; 2021 Mar 03; 13(1):16. PubMed ID: 33658063
    [Abstract] [Full Text] [Related]

  • 43. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
    Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ.
    J Clin Gastroenterol; 2011 Sep 03; 45(8):679-83. PubMed ID: 21301358
    [Abstract] [Full Text] [Related]

  • 44. A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
    Mack I, Schwille-Kiuntke J, Mazurak N, Niesler B, Zimmermann K, Mönnikes H, Enck P.
    Clin Gastroenterol Hepatol; 2022 May 03; 20(5):1039-1047.e9. PubMed ID: 34214682
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS.
    Gastroenterology; 2013 Aug 03; 145(2):329-38.e1. PubMed ID: 23583433
    [Abstract] [Full Text] [Related]

  • 47. Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study.
    Barraza-Ortiz DA, Pérez-López N, Medina-López VM, Minero-Alfaro JI, Zamarripa-Dorsey F, Fernández-Martínez NDC, Llorente-Ramón A, Ramos-Aguilar GA.
    Dig Dis; 2021 Aug 03; 39(3):294-300. PubMed ID: 32810850
    [Abstract] [Full Text] [Related]

  • 48. Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: An explorative study.
    Hong G, Li Y, Yang M, Li G, Qian W, Xiong H, Bai T, Song J, Zhang L, Hou X.
    Neurogastroenterol Motil; 2020 Nov 03; 32(11):e13891. PubMed ID: 32449259
    [Abstract] [Full Text] [Related]

  • 49. Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial.
    Shin SY, Park S, Moon JM, Kim K, Kim JW, Chun J, Lee TH, Choi CH, Microbiome Research Group of the Korean Society for Neurogastroenterology and Motility.
    J Neurogastroenterol Motil; 2022 Oct 30; 28(4):642-654. PubMed ID: 36250371
    [Abstract] [Full Text] [Related]

  • 50. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes.
    Lyra A, Krogius-Kurikka L, Nikkilä J, Malinen E, Kajander K, Kurikka K, Korpela R, Palva A.
    BMC Gastroenterol; 2010 Sep 19; 10():110. PubMed ID: 20849659
    [Abstract] [Full Text] [Related]

  • 51. Effects of an oral synbiotic on the gastrointestinal immune system and microbiota in patients with diarrhea-predominant irritable bowel syndrome.
    Moser AM, Spindelboeck W, Halwachs B, Strohmaier H, Kump P, Gorkiewicz G, Högenauer C.
    Eur J Nutr; 2019 Oct 19; 58(7):2767-2778. PubMed ID: 30251020
    [Abstract] [Full Text] [Related]

  • 52. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis.
    Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT.
    Dig Liver Dis; 2017 Apr 19; 49(4):331-337. PubMed ID: 28179092
    [Abstract] [Full Text] [Related]

  • 53. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
    Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J.
    Arq Gastroenterol; 2013 Apr 19; 50(4):304-9. PubMed ID: 24474234
    [Abstract] [Full Text] [Related]

  • 54. Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics.
    Staudacher HM, Scholz M, Lomer MC, Ralph FS, Irving PM, Lindsay JO, Fava F, Tuohy K, Whelan K.
    Clin Nutr; 2021 Apr 19; 40(4):1861-1870. PubMed ID: 33183883
    [Abstract] [Full Text] [Related]

  • 55. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome.
    Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y.
    Neurogastroenterol Motil; 2012 Jun 19; 24(6):521-30, e248. PubMed ID: 22339879
    [Abstract] [Full Text] [Related]

  • 56. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome.
    Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD.
    BMC Gastroenterol; 2013 Mar 07; 13():45. PubMed ID: 23496803
    [Abstract] [Full Text] [Related]

  • 57. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S, Ida M, Akiho H, Nakashima Y, Matsueda K.
    Clin Gastroenterol Hepatol; 2014 Jun 07; 12(6):953-9.e4. PubMed ID: 24315882
    [Abstract] [Full Text] [Related]

  • 58. Intestinal Microbiome in Irritable Bowel Syndrome before and after Gut-Directed Hypnotherapy.
    Peter J, Fournier C, Keip B, Rittershaus N, Stephanou-Rieser N, Durdevic M, Dejaco C, Michalski M, Moser G.
    Int J Mol Sci; 2018 Nov 16; 19(11):. PubMed ID: 30453528
    [Abstract] [Full Text] [Related]

  • 59. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.
    Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG.
    Gastroenterology; 2014 Jan 16; 146(1):67-75.e5. PubMed ID: 24076059
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.